<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043186</url>
  </required_header>
  <id_info>
    <org_study_id>20010223</org_study_id>
    <nct_id>NCT00043186</nct_id>
  </id_info>
  <brief_title>Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      To determine the effect of denosumab treatment compared with placebo over 12 months on bone
      mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical
      hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12
      months will significantly increase lumbar spine bone mineral density and will be well
      tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CTX Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Creatinine Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Creatinine Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Creatinine Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Creatinine Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine NTX/Creatinine Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Density Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Density Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Density Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Bone Mineral Density Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42</measure>
    <time_frame>Baseline and 42 months</time_frame>
    <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48</measure>
    <time_frame>Baseline and 48 months</time_frame>
    <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Low Bone Mineral Density</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 6 mg every 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 14 mg every 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 30 mg every 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 14 mg every 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 60 mg every 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 100 mg every 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 210 mg every 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab for subcutaneous injection</description>
    <arm_group_label>Denosumab 6 mg every 3 months</arm_group_label>
    <arm_group_label>Denosumab 14 mg every 3 months</arm_group_label>
    <arm_group_label>Denosumab 30 mg every 3 months</arm_group_label>
    <arm_group_label>Denosumab 14 mg every 6 months</arm_group_label>
    <arm_group_label>Denosumab 60 mg every 6 months</arm_group_label>
    <arm_group_label>Denosumab 100 mg every 6 months</arm_group_label>
    <arm_group_label>Denosumab 210 mg every 6 months</arm_group_label>
    <other_name>AMG 162</other_name>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate 70 mg tablets</description>
    <arm_group_label>Alendronate 70 mg</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  women not more than 80 years of age on date of randomization

          -  ≥ 1 year postmenopausal on date of randomization

          -  ambulatory

          -  if ≤ 60 years of age, or had or would require a bilateral oophorectomy, serum follicle
             stimulating hormone (FSH) &gt; 50 mU/mL or serum estradiol &lt; 20 pg/mL

          -  low BMD (BMD T-score ≤ -1.8 at any 1 of the following sites: lumbar spine, femoral
             neck, or total hip; BMD T-scores must not have been &lt; -4.0 at the lumbar spine or -
             3.5 at the femoral neck or total hip)

          -  before any study-specific procedure, including the screening dual X-ray absorptiometry
             (DXA) scan, gave informed consent for participation in the study.

        Exclusion Criteria

          -  fluoride treatment for osteoporosis within the 2 years before the enrollment date

          -  bisphosphonate use within the 12 months before the enrollment date

          -  administration of the following medications within the 6 months before the enrollment
             date

               -  tibolone

               -  Parathyroid hormone (PTH) (or any derivative)

               -  systemic glucocorticosteroids (&gt; 5 mg oral prednisone equivalent per day for &gt; 10
                  days)

               -  inhaled corticosteroids (&gt; 2000 μg per day for &gt; 10 days)

               -  anabolic steroids or testosterone

          -  administration of the following medications within the 3 months before the enrollment
             date

               -  systemic hormone replacement therapy

               -  selective estrogen receptor modulators

               -  calcitonin

               -  calcitriol

          -  current hyper- or hypothyroidism (allowed if stable on thyroid replacement therapy and
             thyroid-stimulating hormone was within the normal range)

          -  current hyper- or hypoparathyroidism

          -  albumin-adjusted serum calcium &lt; 8.5 mg/dL (&lt; 2.125 mol/L)

          -  osteomalacia

          -  rheumatoid arthritis

          -  Paget's disease

          -  malignancy within the 5 years before enrollment (except cervical carcinoma in situ or
             basal cell carcinoma, which were acceptable)

          -  renal disease; ie, creatinine clearance ≤ 35 mL/min

          -  any bone disease, other than osteoporosis, which could interfere with the
             interpretation of the findings (eg, osteogenesis imperfecta or osteopetrosis)

          -  malabsorption syndrome

          -  weight, height, or girth that could preclude accurate DXA measurements

          -  &lt; 2 lumbar vertebrae (L1 through L4) evaluable by DXA

          -  recent long bone fracture (within 6 months)

          -  osteoporotic-related fracture (ie, crush or wedge vertebral fracture or hip fracture)
             known or suspected to have occurred within 2 years of randomization

          -  &gt; 1 single, grade 1 vertebral fracture

          -  currently enrolled in or had participated within the previous 30 days in other
             investigational device or drug trial(s) (For some trials, this may have been allowed
             after discussion and written approval from Amgen.)

          -  known sensitivity to mammalian-derived drug preparations (eg, Herceptin®)

          -  any organic or psychiatric disorder, serum chemistry, or hematology that, in the
             opinion of the investigator, could have prevented the subject from completing the
             study or have interfered with the interpretation of the study results

          -  self-reported alcohol or drug abuse within the previous 12 months

          -  any disorder that compromised the ability to give truly informed consent for
             participation in the study

          -  previous administration of denosumab

          -  known sensitivity or contraindication to alendronate

          -  known sensitivity or contraindication to tetracycline derivatives (subjects in the
             biopsy substudy only).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom. 2008 Jul-Sep;11(3):351-9. doi: 10.1016/j.jocd.2008.04.001. Epub 2008 May 20.</citation>
    <PMID>18495508</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007 Dec;22(12):1832-41.</citation>
    <PMID>17708711</PMID>
  </results_reference>
  <results_reference>
    <citation>McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 Feb 23;354(8):821-31.</citation>
    <PMID>16495394</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-9. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26.</citation>
    <PMID>18539106</PMID>
  </results_reference>
  <results_reference>
    <citation>Peterson MC, Riggs MM. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone. 2010 Jan;46(1):49-63. doi: 10.1016/j.bone.2009.08.053. Epub 2009 Sep 2.</citation>
    <PMID>19732857</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2002</study_first_submitted>
  <study_first_submitted_qc>August 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2002</study_first_posted>
  <results_first_submitted>December 22, 2009</results_first_submitted>
  <results_first_submitted_qc>June 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2010</results_first_posted>
  <disposition_first_submitted>November 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2009</disposition_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone loss</keyword>
  <keyword>osteoporosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 11-May-2002 Last Subject Enrolled: 30-Apr-2003</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P2">
          <title>Denosumab 6 mg Q3M</title>
          <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P3">
          <title>Denosumab 14 mg Q3M</title>
          <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P4">
          <title>Denosumab 30 mg Q3M</title>
          <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
        </group>
        <group group_id="P5">
          <title>Denosumab 14 mg Q6M</title>
          <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P6">
          <title>Denosumab 60 mg Q6M</title>
          <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
        </group>
        <group group_id="P7">
          <title>Denosumab 100 mg Q6M</title>
          <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P8">
          <title>Denosumab 210 mg Q6M</title>
          <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="P9">
          <title>Alendronate 70 mg</title>
          <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="54"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="42"/>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="31"/>
                <participants group_id="P9" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab 6 mg Q3M</title>
          <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B3">
          <title>Denosumab 14 mg Q3M</title>
          <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B4">
          <title>Denosumab 30 mg Q3M</title>
          <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
        </group>
        <group group_id="B5">
          <title>Denosumab 14 mg Q6M</title>
          <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B6">
          <title>Denosumab 60 mg Q6M</title>
          <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
        </group>
        <group group_id="B7">
          <title>Denosumab 100 mg Q6M</title>
          <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B8">
          <title>Denosumab 210 mg Q6M</title>
          <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="B9">
          <title>Alendronate 70 mg</title>
          <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="54"/>
            <count group_id="B6" value="47"/>
            <count group_id="B7" value="42"/>
            <count group_id="B8" value="47"/>
            <count group_id="B9" value="47"/>
            <count group_id="B10" value="412"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="9.1"/>
                    <measurement group_id="B2" value="62.8" spread="8.6"/>
                    <measurement group_id="B3" value="62.3" spread="6"/>
                    <measurement group_id="B4" value="61.2" spread="8.5"/>
                    <measurement group_id="B5" value="61.4" spread="8.1"/>
                    <measurement group_id="B6" value="63.1" spread="8.1"/>
                    <measurement group_id="B7" value="64.9" spread="8.2"/>
                    <measurement group_id="B8" value="60.5" spread="7.8"/>
                    <measurement group_id="B9" value="62.8" spread="8.2"/>
                    <measurement group_id="B10" value="62.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="42"/>
                    <measurement group_id="B8" value="47"/>
                    <measurement group_id="B9" value="47"/>
                    <measurement group_id="B10" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="42"/>
                    <measurement group_id="B9" value="40"/>
                    <measurement group_id="B10" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.48"/>
                    <measurement group_id="O2" value="4.41" spread="0.50"/>
                    <measurement group_id="O3" value="4.71" spread="0.50"/>
                    <measurement group_id="O4" value="6.69" spread="0.54"/>
                    <measurement group_id="O5" value="3.03" spread="0.43"/>
                    <measurement group_id="O6" value="4.55" spread="0.47"/>
                    <measurement group_id="O7" value="5.52" spread="0.49"/>
                    <measurement group_id="O8" value="5.07" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.59</ci_lower_limit>
            <ci_upper_limit>7.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.01</ci_lower_limit>
            <ci_upper_limit>7.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.07</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.60</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.13</ci_lower_limit>
            <ci_upper_limit>8.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.19</ci_lower_limit>
            <ci_upper_limit>6.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.88</ci_lower_limit>
            <ci_upper_limit>6.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CTX Percent Change From Baseline at Month 12</title>
        <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CTX Percent Change From Baseline at Month 12</title>
          <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.699" lower_limit="-20.74" upper_limit="28.3"/>
                    <measurement group_id="O2" value="-61.366" lower_limit="-74.42" upper_limit="-41.92"/>
                    <measurement group_id="O3" value="-77.989" lower_limit="-87.02" upper_limit="-55.37"/>
                    <measurement group_id="O4" value="-87.238" lower_limit="-90.53" upper_limit="-71.25"/>
                    <measurement group_id="O5" value="-12.054" lower_limit="-38.48" upper_limit="10.69"/>
                    <measurement group_id="O6" value="-70.757" lower_limit="-81.47" upper_limit="-55.78"/>
                    <measurement group_id="O7" value="-78.617" lower_limit="-85.85" upper_limit="-60.95"/>
                    <measurement group_id="O8" value="-84.107" lower_limit="-90.70" upper_limit="-77.85"/>
                    <measurement group_id="O9" value="-72.603" lower_limit="-81.72" upper_limit="-59.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Creatinine Percent Change From Baseline at Month 12</title>
        <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Creatinine Percent Change From Baseline at Month 12</title>
          <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.300" lower_limit="-23.06" upper_limit="39.84"/>
                    <measurement group_id="O2" value="-40.018" lower_limit="-49.76" upper_limit="-6.38"/>
                    <measurement group_id="O3" value="-54.688" lower_limit="-66.80" upper_limit="-23.33"/>
                    <measurement group_id="O4" value="-60.652" lower_limit="-73.16" upper_limit="-46.40"/>
                    <measurement group_id="O5" value="-2.027" lower_limit="-20.30" upper_limit="10.84"/>
                    <measurement group_id="O6" value="-36.523" lower_limit="-54.67" upper_limit="-16.06"/>
                    <measurement group_id="O7" value="-51.256" lower_limit="-67.31" upper_limit="-22.17"/>
                    <measurement group_id="O8" value="-58.502" lower_limit="-70.55" upper_limit="-29.84"/>
                    <measurement group_id="O9" value="-45.409" lower_limit="-59.96" upper_limit="-22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.68"/>
                    <measurement group_id="O2" value="7.42" spread="0.69"/>
                    <measurement group_id="O3" value="7.21" spread="0.68"/>
                    <measurement group_id="O4" value="8.83" spread="0.76"/>
                    <measurement group_id="O5" value="3.94" spread="0.60"/>
                    <measurement group_id="O6" value="7.19" spread="0.62"/>
                    <measurement group_id="O7" value="7.31" spread="0.67"/>
                    <measurement group_id="O8" value="7.86" spread="0.65"/>
                    <measurement group_id="O9" value="6.09" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.56</ci_lower_limit>
            <ci_upper_limit>9.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.31</ci_lower_limit>
            <ci_upper_limit>10.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.71</ci_lower_limit>
            <ci_upper_limit>10.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.69</ci_lower_limit>
            <ci_upper_limit>10.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.43</ci_lower_limit>
            <ci_upper_limit>6.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.14</ci_lower_limit>
            <ci_upper_limit>12.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.62</ci_lower_limit>
            <ci_upper_limit>10.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.80</ci_lower_limit>
            <ci_upper_limit>10.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="0.82"/>
                    <measurement group_id="O2" value="8.57" spread="0.80"/>
                    <measurement group_id="O3" value="9.17" spread="0.89"/>
                    <measurement group_id="O4" value="1.94" spread="0.94"/>
                    <measurement group_id="O5" value="7.99" spread="0.72"/>
                    <measurement group_id="O6" value="9.04" spread="0.74"/>
                    <measurement group_id="O7" value="10.63" spread="0.82"/>
                    <measurement group_id="O8" value="0.85" spread="0.72"/>
                    <measurement group_id="O9" value="4.70" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.32</ci_lower_limit>
            <ci_upper_limit>8.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>4.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.19</ci_lower_limit>
            <ci_upper_limit>14.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.74</ci_lower_limit>
            <ci_upper_limit>12.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.69</ci_lower_limit>
            <ci_upper_limit>11.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>6.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.63</ci_lower_limit>
            <ci_upper_limit>13.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.16</ci_lower_limit>
            <ci_upper_limit>12.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.70"/>
                    <measurement group_id="O2" value="7.21" spread="2.13"/>
                    <measurement group_id="O3" value="10.04" spread="1.86"/>
                    <measurement group_id="O4" value="5.06" spread="2.13"/>
                    <measurement group_id="O5" value="9.46" spread="1.24"/>
                    <measurement group_id="O6" value="9.59" spread="1.40"/>
                    <measurement group_id="O7" value="9.99" spread="1.93"/>
                    <measurement group_id="O8" value="1.06" spread="1.80"/>
                    <measurement group_id="O9" value="6.51" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>9.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.07</ci_lower_limit>
            <ci_upper_limit>5.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.72</ci_lower_limit>
            <ci_upper_limit>14.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.15</ci_lower_limit>
            <ci_upper_limit>12.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.11</ci_lower_limit>
            <ci_upper_limit>12.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>9.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.94</ci_lower_limit>
            <ci_upper_limit>13.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>11.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="1.11"/>
                    <measurement group_id="O2" value="9.35" spread="1.09"/>
                    <measurement group_id="O3" value="9.93" spread="1.20"/>
                    <measurement group_id="O4" value="9.03" spread="1.33"/>
                    <measurement group_id="O5" value="10.10" spread="0.96"/>
                    <measurement group_id="O6" value="10.34" spread="0.96"/>
                    <measurement group_id="O7" value="11.76" spread="1.13"/>
                    <measurement group_id="O8" value="2.50" spread="1.07"/>
                    <measurement group_id="O9" value="4.54" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.97</ci_lower_limit>
            <ci_upper_limit>9.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>7.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.08</ci_lower_limit>
            <ci_upper_limit>17.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.94</ci_lower_limit>
            <ci_upper_limit>15.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.66</ci_lower_limit>
            <ci_upper_limit>15.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.12</ci_lower_limit>
            <ci_upper_limit>14.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.15</ci_lower_limit>
            <ci_upper_limit>15.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.72</ci_lower_limit>
            <ci_upper_limit>14.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CTX Percent Change From Baseline at Month 24</title>
        <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CTX Percent Change From Baseline at Month 24</title>
          <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.940" lower_limit="-23.22" upper_limit="20.61"/>
                    <measurement group_id="O2" value="-50.687" lower_limit="-73.73" upper_limit="-27.21"/>
                    <measurement group_id="O3" value="-74.078" lower_limit="-84.96" upper_limit="-52.32"/>
                    <measurement group_id="O4" value="-83.985" lower_limit="-89.66" upper_limit="-74.02"/>
                    <measurement group_id="O5" value="-8.467" lower_limit="-24.02" upper_limit="25.84"/>
                    <measurement group_id="O6" value="-68.437" lower_limit="-81.80" upper_limit="-44.39"/>
                    <measurement group_id="O7" value="-80.460" lower_limit="-89.31" upper_limit="-43.68"/>
                    <measurement group_id="O8" value="-85.680" lower_limit="-90.94" upper_limit="-78.32"/>
                    <measurement group_id="O9" value="-69.386" lower_limit="-79.82" upper_limit="-52.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.622</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CTX Percent Change From Baseline at Month 36</title>
        <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CTX Percent Change From Baseline at Month 36</title>
          <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.577" lower_limit="-28.96" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-62.298" lower_limit="-81.94" upper_limit="-42.09"/>
                    <measurement group_id="O3" value="-53.643" lower_limit="-82.23" upper_limit="-34.04"/>
                    <measurement group_id="O4" value="56.286" lower_limit="21.35" upper_limit="73.85"/>
                    <measurement group_id="O5" value="-57.500" lower_limit="-75.77" upper_limit="-23.56"/>
                    <measurement group_id="O6" value="-54.418" lower_limit="-72.02" upper_limit="-12.53"/>
                    <measurement group_id="O7" value="-45.057" lower_limit="-81.69" upper_limit="-11.29"/>
                    <measurement group_id="O8" value="72.135" lower_limit="34.18" upper_limit="136.00"/>
                    <measurement group_id="O9" value="-33.982" lower_limit="-56.86" upper_limit="-21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CTX Percent Change From Baseline at Month 42</title>
        <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participantswith non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CTX Percent Change From Baseline at Month 42</title>
          <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participantswith non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.279" lower_limit="-31.66" upper_limit="18.31"/>
                    <measurement group_id="O2" value="-63.543" lower_limit="-83.99" upper_limit="-38.15"/>
                    <measurement group_id="O3" value="-40.827" lower_limit="-85.17" upper_limit="-13.72"/>
                    <measurement group_id="O4" value="-62.334" lower_limit="-88.37" upper_limit="-27.85"/>
                    <measurement group_id="O5" value="-46.408" lower_limit="-80.65" upper_limit="-32.46"/>
                    <measurement group_id="O6" value="-57.255" lower_limit="-74.60" upper_limit="-23.04"/>
                    <measurement group_id="O7" value="-56.377" lower_limit="-77.35" upper_limit="-20.98"/>
                    <measurement group_id="O8" value="33.999" lower_limit="0.15" upper_limit="49.68"/>
                    <measurement group_id="O9" value="-46.743" lower_limit="-58.94" upper_limit="-26.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CTX Percent Change From Baseline at Month 48</title>
        <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CTX Percent Change From Baseline at Month 48</title>
          <description>Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.561" lower_limit="-33.09" upper_limit="6.61"/>
                    <measurement group_id="O2" value="-40.016" lower_limit="-80.76" upper_limit="0.11"/>
                    <measurement group_id="O3" value="-34.999" lower_limit="-78.25" upper_limit="-7.84"/>
                    <measurement group_id="O4" value="-52.656" lower_limit="-78.86" upper_limit="-5.25"/>
                    <measurement group_id="O5" value="-39.899" lower_limit="-73.80" upper_limit="-9.78"/>
                    <measurement group_id="O6" value="-51.494" lower_limit="-78.57" upper_limit="-14.62"/>
                    <measurement group_id="O7" value="-36.480" lower_limit="-70.12" upper_limit="-18.54"/>
                    <measurement group_id="O8" value="7.067" lower_limit="-17.06" upper_limit="31.25"/>
                    <measurement group_id="O9" value="-43.724" lower_limit="-56.28" upper_limit="-14.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Creatinine Percent Change From Baseline at Month 24</title>
        <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Creatinine Percent Change From Baseline at Month 24</title>
          <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.422" lower_limit="-5.30" upper_limit="56.37"/>
                    <measurement group_id="O2" value="-19.699" lower_limit="-51.71" upper_limit="1.61"/>
                    <measurement group_id="O3" value="-37.691" lower_limit="-60.65" upper_limit="-4.19"/>
                    <measurement group_id="O4" value="-49.907" lower_limit="-68.26" upper_limit="-20.43"/>
                    <measurement group_id="O5" value="2.134" lower_limit="-15.60" upper_limit="45.10"/>
                    <measurement group_id="O6" value="-32.303" lower_limit="-54.06" upper_limit="15.35"/>
                    <measurement group_id="O7" value="-37.001" lower_limit="-72.15" upper_limit="11.74"/>
                    <measurement group_id="O8" value="-47.105" lower_limit="-76.14" upper_limit="-24.75"/>
                    <measurement group_id="O9" value="-44.482" lower_limit="-59.46" upper_limit="-8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Creatinine Percent Change From Baseline at Month 36</title>
        <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Creatinine Percent Change From Baseline at Month 36</title>
          <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.508" lower_limit="-21.60" upper_limit="11.89"/>
                    <measurement group_id="O2" value="-33.294" lower_limit="-56.03" upper_limit="-3.63"/>
                    <measurement group_id="O3" value="-47.752" lower_limit="-58.74" upper_limit="-16.01"/>
                    <measurement group_id="O4" value="82.910" lower_limit="32.79" upper_limit="108.70"/>
                    <measurement group_id="O5" value="-44.301" lower_limit="-58.12" upper_limit="-15.68"/>
                    <measurement group_id="O6" value="-36.874" lower_limit="-57.37" upper_limit="-5.32"/>
                    <measurement group_id="O7" value="-27.174" lower_limit="-56.30" upper_limit="25.52"/>
                    <measurement group_id="O8" value="70.997" lower_limit="24.80" upper_limit="125.90"/>
                    <measurement group_id="O9" value="-15.627" lower_limit="-40.75" upper_limit="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Creatinine Percent Change From Baseline at Month 42</title>
        <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Creatinine Percent Change From Baseline at Month 42</title>
          <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.102" lower_limit="-31.05" upper_limit="30.83"/>
                    <measurement group_id="O2" value="-40.741" lower_limit="-60.82" upper_limit="-12.95"/>
                    <measurement group_id="O3" value="-40.043" lower_limit="-65.63" upper_limit="-9.12"/>
                    <measurement group_id="O4" value="-58.893" lower_limit="-67.49" upper_limit="-14.26"/>
                    <measurement group_id="O5" value="-47.188" lower_limit="-69.64" upper_limit="-25.46"/>
                    <measurement group_id="O6" value="-39.269" lower_limit="-64.25" upper_limit="-4.97"/>
                    <measurement group_id="O7" value="-46.674" lower_limit="-63.98" upper_limit="-9.33"/>
                    <measurement group_id="O8" value="26.277" lower_limit="-16.99" upper_limit="88.12"/>
                    <measurement group_id="O9" value="-33.102" lower_limit="-53.10" upper_limit="-19.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine NTX/Creatinine Percent Change From Baseline at Month 48</title>
        <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine NTX/Creatinine Percent Change From Baseline at Month 48</title>
          <description>Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.064" lower_limit="-36.94" upper_limit="32.77"/>
                    <measurement group_id="O2" value="-23.311" lower_limit="-62.33" upper_limit="11.43"/>
                    <measurement group_id="O3" value="-38.002" lower_limit="-67.11" upper_limit="-15.91"/>
                    <measurement group_id="O4" value="-50.864" lower_limit="-80.48" upper_limit="-9.49"/>
                    <measurement group_id="O5" value="-46.128" lower_limit="-64.44" upper_limit="-14.07"/>
                    <measurement group_id="O6" value="-40.375" lower_limit="-70.06" upper_limit="-0.46"/>
                    <measurement group_id="O7" value="-41.998" lower_limit="-70.45" upper_limit="-6.62"/>
                    <measurement group_id="O8" value="7.884" lower_limit="-35.02" upper_limit="72.97"/>
                    <measurement group_id="O9" value="-32.198" lower_limit="-59.36" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.37"/>
                    <measurement group_id="O2" value="2.89" spread="0.38"/>
                    <measurement group_id="O3" value="2.45" spread="0.39"/>
                    <measurement group_id="O4" value="3.32" spread="0.42"/>
                    <measurement group_id="O5" value="1.94" spread="0.33"/>
                    <measurement group_id="O6" value="3.56" spread="0.36"/>
                    <measurement group_id="O7" value="2.53" spread="0.38"/>
                    <measurement group_id="O8" value="2.33" spread="0.36"/>
                    <measurement group_id="O9" value="2.11" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.90</ci_lower_limit>
            <ci_upper_limit>3.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>5.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>3.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.83</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.99</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.43</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="0.44"/>
                    <measurement group_id="O2" value="4.04" spread="0.45"/>
                    <measurement group_id="O3" value="3.55" spread="0.44"/>
                    <measurement group_id="O4" value="5.03" spread="0.50"/>
                    <measurement group_id="O5" value="2.62" spread="0.39"/>
                    <measurement group_id="O6" value="4.96" spread="0.40"/>
                    <measurement group_id="O7" value="3.67" spread="0.44"/>
                    <measurement group_id="O8" value="4.18" spread="0.43"/>
                    <measurement group_id="O9" value="3.27" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.04</ci_lower_limit>
            <ci_upper_limit>6.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.93</ci_lower_limit>
            <ci_upper_limit>7.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.40</ci_lower_limit>
            <ci_upper_limit>6.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.76</ci_lower_limit>
            <ci_upper_limit>8.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.41</ci_lower_limit>
            <ci_upper_limit>5.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.69</ci_lower_limit>
            <ci_upper_limit>8.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.29</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.76</ci_lower_limit>
            <ci_upper_limit>7.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.60"/>
                    <measurement group_id="O2" value="4.79" spread="0.58"/>
                    <measurement group_id="O3" value="4.41" spread="0.65"/>
                    <measurement group_id="O4" value="-1.23" spread="0.68"/>
                    <measurement group_id="O5" value="4.31" spread="0.52"/>
                    <measurement group_id="O6" value="5.83" spread="0.54"/>
                    <measurement group_id="O7" value="4.33" spread="0.60"/>
                    <measurement group_id="O8" value="-1.43" spread="0.53"/>
                    <measurement group_id="O9" value="0.93" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.54</ci_lower_limit>
            <ci_upper_limit>8.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.13</ci_lower_limit>
            <ci_upper_limit>10.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.62</ci_lower_limit>
            <ci_upper_limit>8.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.56</ci_lower_limit>
            <ci_upper_limit>8.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.02</ci_lower_limit>
            <ci_upper_limit>9.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 42</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 42</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="1.16"/>
                    <measurement group_id="O2" value="5.01" spread="1.43"/>
                    <measurement group_id="O3" value="3.98" spread="1.28"/>
                    <measurement group_id="O4" value="2.37" spread="1.46"/>
                    <measurement group_id="O5" value="4.54" spread="0.85"/>
                    <measurement group_id="O6" value="6.34" spread="0.98"/>
                    <measurement group_id="O7" value="4.70" spread="1.32"/>
                    <measurement group_id="O8" value="-2.67" spread="1.23"/>
                    <measurement group_id="O9" value="2.98" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>8.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.10</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.14</ci_lower_limit>
            <ci_upper_limit>10.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.26</ci_lower_limit>
            <ci_upper_limit>11.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.59</ci_lower_limit>
            <ci_upper_limit>9.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>8.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>9.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.28</ci_lower_limit>
            <ci_upper_limit>10.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 48</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 48</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.52" spread="0.65"/>
                    <measurement group_id="O2" value="5.45" spread="0.63"/>
                    <measurement group_id="O3" value="4.03" spread="0.70"/>
                    <measurement group_id="O4" value="3.86" spread="0.77"/>
                    <measurement group_id="O5" value="4.82" spread="0.56"/>
                    <measurement group_id="O6" value="6.06" spread="0.56"/>
                    <measurement group_id="O7" value="4.99" spread="0.66"/>
                    <measurement group_id="O8" value="-1.37" spread="0.62"/>
                    <measurement group_id="O9" value="1.17" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.97</ci_lower_limit>
            <ci_upper_limit>6.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>3.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.74</ci_lower_limit>
            <ci_upper_limit>10.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.95</ci_lower_limit>
            <ci_upper_limit>11.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.70</ci_lower_limit>
            <ci_upper_limit>9.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.45</ci_lower_limit>
            <ci_upper_limit>9.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.72</ci_lower_limit>
            <ci_upper_limit>9.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.23</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="0.50"/>
                    <measurement group_id="O2" value="0.89" spread="0.52"/>
                    <measurement group_id="O3" value="0.40" spread="0.53"/>
                    <measurement group_id="O4" value="1.10" spread="0.55"/>
                    <measurement group_id="O5" value="0.94" spread="0.46"/>
                    <measurement group_id="O6" value="1.29" spread="0.48"/>
                    <measurement group_id="O7" value="1.07" spread="0.50"/>
                    <measurement group_id="O8" value="1.09" spread="0.51"/>
                    <measurement group_id="O9" value="-0.53" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.94</ci_lower_limit>
            <ci_upper_limit>4.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>4.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>4.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>3.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="0.56"/>
                    <measurement group_id="O2" value="1.31" spread="0.57"/>
                    <measurement group_id="O3" value="0.62" spread="0.58"/>
                    <measurement group_id="O4" value="1.30" spread="0.63"/>
                    <measurement group_id="O5" value="2.48" spread="0.52"/>
                    <measurement group_id="O6" value="1.89" spread="0.51"/>
                    <measurement group_id="O7" value="1.48" spread="0.56"/>
                    <measurement group_id="O8" value="0.81" spread="0.56"/>
                    <measurement group_id="O9" value="-0.78" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>5.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.55</ci_lower_limit>
            <ci_upper_limit>5.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.23</ci_lower_limit>
            <ci_upper_limit>6.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.78</ci_lower_limit>
            <ci_upper_limit>6.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.48</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64" spread="0.63"/>
                    <measurement group_id="O2" value="1.99" spread="0.60"/>
                    <measurement group_id="O3" value="1.06" spread="0.69"/>
                    <measurement group_id="O4" value="1.05" spread="0.71"/>
                    <measurement group_id="O5" value="2.08" spread="0.55"/>
                    <measurement group_id="O6" value="2.69" spread="0.55"/>
                    <measurement group_id="O7" value="1.92" spread="0.62"/>
                    <measurement group_id="O8" value="0.12" spread="0.57"/>
                    <measurement group_id="O9" value="-0.95" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>4.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>5.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.87</ci_lower_limit>
            <ci_upper_limit>7.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.75</ci_lower_limit>
            <ci_upper_limit>7.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.12</ci_lower_limit>
            <ci_upper_limit>7.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>6.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.92</ci_lower_limit>
            <ci_upper_limit>6.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.96</ci_lower_limit>
            <ci_upper_limit>7.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.59" spread="3.00"/>
                    <measurement group_id="O2" value="1.00" spread="3.26"/>
                    <measurement group_id="O3" value="0.82" spread="2.92"/>
                    <measurement group_id="O4" value="-3.91" spread="3.39"/>
                    <measurement group_id="O5" value="1.29" spread="2.14"/>
                    <measurement group_id="O6" value="-0.87" spread="2.93"/>
                    <measurement group_id="O7" value="0.02" spread="5.00"/>
                    <measurement group_id="O8" value="0.59" spread="2.52"/>
                    <measurement group_id="O9" value="-3.32" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.496</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.16</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.38</ci_lower_limit>
            <ci_upper_limit>19.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>14.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.54</ci_lower_limit>
            <ci_upper_limit>11.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>17.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>17.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>16.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>14.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="28"/>
                <count group_id="O9" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.67" spread="0.75"/>
                    <measurement group_id="O2" value="1.04" spread="0.73"/>
                    <measurement group_id="O3" value="1.42" spread="0.84"/>
                    <measurement group_id="O4" value="1.77" spread="0.91"/>
                    <measurement group_id="O5" value="1.74" spread="0.66"/>
                    <measurement group_id="O6" value="1.71" spread="0.65"/>
                    <measurement group_id="O7" value="1.37" spread="0.75"/>
                    <measurement group_id="O8" value="-0.94" spread="0.74"/>
                    <measurement group_id="O9" value="-2.67" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.48</ci_lower_limit>
            <ci_upper_limit>8.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.19</ci_lower_limit>
            <ci_upper_limit>8.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.91</ci_lower_limit>
            <ci_upper_limit>8.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.70</ci_lower_limit>
            <ci_upper_limit>7.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>5.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.00</ci_lower_limit>
            <ci_upper_limit>8.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.49</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.46"/>
                    <measurement group_id="O2" value="1.82" spread="0.45"/>
                    <measurement group_id="O3" value="1.80" spread="0.46"/>
                    <measurement group_id="O4" value="2.74" spread="0.51"/>
                    <measurement group_id="O5" value="0.55" spread="0.41"/>
                    <measurement group_id="O6" value="2.51" spread="0.43"/>
                    <measurement group_id="O7" value="1.78" spread="0.46"/>
                    <measurement group_id="O8" value="2.08" spread="0.44"/>
                    <measurement group_id="O9" value="1.51" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>3.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 24</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 24</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.53"/>
                    <measurement group_id="O2" value="2.59" spread="0.54"/>
                    <measurement group_id="O3" value="2.91" spread="0.53"/>
                    <measurement group_id="O4" value="4.44" spread="0.62"/>
                    <measurement group_id="O5" value="0.89" spread="0.49"/>
                    <measurement group_id="O6" value="2.57" spread="0.49"/>
                    <measurement group_id="O7" value="3.00" spread="0.53"/>
                    <measurement group_id="O8" value="2.75" spread="0.53"/>
                    <measurement group_id="O9" value="1.50" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.95</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.19</ci_lower_limit>
            <ci_upper_limit>6.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>3.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.53</ci_lower_limit>
            <ci_upper_limit>7.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.12</ci_lower_limit>
            <ci_upper_limit>5.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>5.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 36</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 36</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="0.94"/>
                    <measurement group_id="O2" value="3.14" spread="0.88"/>
                    <measurement group_id="O3" value="3.04" spread="0.98"/>
                    <measurement group_id="O4" value="2.34" spread="1.09"/>
                    <measurement group_id="O5" value="2.04" spread="0.83"/>
                    <measurement group_id="O6" value="2.80" spread="0.80"/>
                    <measurement group_id="O7" value="2.59" spread="0.94"/>
                    <measurement group_id="O8" value="-0.29" spread="0.83"/>
                    <measurement group_id="O9" value="4.55" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.63</ci_lower_limit>
            <ci_upper_limit>8.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>6.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>6.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>7.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>7.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 42</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 42</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="1.76"/>
                    <measurement group_id="O2" value="1.90" spread="3.71"/>
                    <measurement group_id="O3" value="4.05" spread="1.70"/>
                    <measurement group_id="O4" value="8.85" spread="3.07"/>
                    <measurement group_id="O5" value="3.72" spread="1.97"/>
                    <measurement group_id="O6" value="4.92" spread="1.83"/>
                    <measurement group_id="O7" value="3.79" spread="3.63"/>
                    <measurement group_id="O8" value="-0.75" spread="1.50"/>
                    <measurement group_id="O9" value="2.85" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.73</ci_lower_limit>
            <ci_upper_limit>13.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.70</ci_lower_limit>
            <ci_upper_limit>9.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>9.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.55</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.51</ci_lower_limit>
            <ci_upper_limit>8.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.484</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>8.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.82</ci_lower_limit>
            <ci_upper_limit>11.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 48</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Bone Mineral Density Percent Change From Baseline at Month 48</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="0.99"/>
                    <measurement group_id="O2" value="3.68" spread="0.98"/>
                    <measurement group_id="O3" value="3.38" spread="1.07"/>
                    <measurement group_id="O4" value="3.76" spread="1.27"/>
                    <measurement group_id="O5" value="3.42" spread="0.86"/>
                    <measurement group_id="O6" value="3.43" spread="0.87"/>
                    <measurement group_id="O7" value="3.68" spread="1.03"/>
                    <measurement group_id="O8" value="-0.29" spread="0.96"/>
                    <measurement group_id="O9" value="4.49" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.35</ci_lower_limit>
            <ci_upper_limit>9.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>4.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.50</ci_lower_limit>
            <ci_upper_limit>8.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.51</ci_lower_limit>
            <ci_upper_limit>8.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.44</ci_lower_limit>
            <ci_upper_limit>8.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.25</ci_lower_limit>
            <ci_upper_limit>9.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.13</ci_lower_limit>
            <ci_upper_limit>8.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.58</ci_lower_limit>
            <ci_upper_limit>8.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12</title>
        <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12</title>
          <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 12.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.609" lower_limit="-26.46" upper_limit="30.31"/>
                    <measurement group_id="O2" value="-62.716" lower_limit="-77.57" upper_limit="-47.64"/>
                    <measurement group_id="O3" value="-60.098" lower_limit="-76.61" upper_limit="-41.34"/>
                    <measurement group_id="O4" value="-70.256" lower_limit="-80.58" upper_limit="-55.16"/>
                    <measurement group_id="O5" value="-39.474" lower_limit="-64.97" upper_limit="-13.73"/>
                    <measurement group_id="O6" value="-65.215" lower_limit="-77.11" upper_limit="-51.79"/>
                    <measurement group_id="O7" value="-61.979" lower_limit="-74.25" upper_limit="-50.61"/>
                    <measurement group_id="O8" value="-67.634" lower_limit="-75.90" upper_limit="-50.19"/>
                    <measurement group_id="O9" value="-61.059" lower_limit="-69.89" upper_limit="-46.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24</title>
        <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24</title>
          <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 24.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.464" lower_limit="-20.18" upper_limit="52.94"/>
                    <measurement group_id="O2" value="-41.225" lower_limit="-65.61" upper_limit="-22.04"/>
                    <measurement group_id="O3" value="-47.597" lower_limit="-69.11" upper_limit="-16.28"/>
                    <measurement group_id="O4" value="-57.905" lower_limit="-66.41" upper_limit="-22.36"/>
                    <measurement group_id="O5" value="-22.350" lower_limit="-44.05" upper_limit="0.50"/>
                    <measurement group_id="O6" value="-43.448" lower_limit="-62.70" upper_limit="-18.28"/>
                    <measurement group_id="O7" value="-50.176" lower_limit="-64.82" upper_limit="-23.14"/>
                    <measurement group_id="O8" value="-48.833" lower_limit="-71.34" upper_limit="-27.38"/>
                    <measurement group_id="O9" value="-48.778" lower_limit="-58.87" upper_limit="-25.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36</title>
        <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36</title>
          <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 36.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.955" lower_limit="-28.21" upper_limit="45.67"/>
                    <measurement group_id="O2" value="-39.012" lower_limit="-66.11" upper_limit="-12.10"/>
                    <measurement group_id="O3" value="-56.021" lower_limit="-69.45" upper_limit="-21.31"/>
                    <measurement group_id="O4" value="22.343" lower_limit="-0.27" upper_limit="49.28"/>
                    <measurement group_id="O5" value="-47.500" lower_limit="-63.87" upper_limit="-32.19"/>
                    <measurement group_id="O6" value="-42.541" lower_limit="-64.46" upper_limit="-24.35"/>
                    <measurement group_id="O7" value="-47.418" lower_limit="-57.70" upper_limit="-22.78"/>
                    <measurement group_id="O8" value="61.747" lower_limit="14.65" upper_limit="101.28"/>
                    <measurement group_id="O9" value="-8.209" lower_limit="-40.84" upper_limit="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42</title>
        <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 42 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42</title>
          <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 42.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.288" lower_limit="-25.01" upper_limit="51.68"/>
                    <measurement group_id="O2" value="-40.182" lower_limit="-65.62" upper_limit="-11.21"/>
                    <measurement group_id="O3" value="-40.819" lower_limit="-64.78" upper_limit="-6.13"/>
                    <measurement group_id="O4" value="-52.684" lower_limit="-67.62" upper_limit="-34.69"/>
                    <measurement group_id="O5" value="-53.763" lower_limit="-62.49" upper_limit="-28.55"/>
                    <measurement group_id="O6" value="-44.892" lower_limit="-62.36" upper_limit="-25.45"/>
                    <measurement group_id="O7" value="-48.303" lower_limit="-59.51" upper_limit="-18.60"/>
                    <measurement group_id="O8" value="17.841" lower_limit="4.18" upper_limit="82.99"/>
                    <measurement group_id="O9" value="-22.069" lower_limit="-41.00" upper_limit="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48</title>
        <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab 6 mg Q3M</title>
            <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O3">
            <title>Denosumab 14 mg Q3M</title>
            <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O4">
            <title>Denosumab 30 mg Q3M</title>
            <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
          </group>
          <group group_id="O5">
            <title>Denosumab 14 mg Q6M</title>
            <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O6">
            <title>Denosumab 60 mg Q6M</title>
            <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
          </group>
          <group group_id="O7">
            <title>Denosumab 100 mg Q6M</title>
            <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O8">
            <title>Denosumab 210 mg Q6M</title>
            <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
          </group>
          <group group_id="O9">
            <title>Alendronate 70 mg</title>
            <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48</title>
          <description>Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.</description>
          <population>Randomized participants with non-missing Baseline and non-missing value at Month 48.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.122" lower_limit="-28.72" upper_limit="59.58"/>
                    <measurement group_id="O2" value="-34.727" lower_limit="-56.34" upper_limit="3.83"/>
                    <measurement group_id="O3" value="-45.779" lower_limit="-60.49" upper_limit="9.42"/>
                    <measurement group_id="O4" value="-47.770" lower_limit="-60.61" upper_limit="-30.76"/>
                    <measurement group_id="O5" value="-46.286" lower_limit="-57.67" upper_limit="-24.26"/>
                    <measurement group_id="O6" value="-34.361" lower_limit="-59.73" upper_limit="-9.38"/>
                    <measurement group_id="O7" value="-42.653" lower_limit="-61.39" upper_limit="-17.29"/>
                    <measurement group_id="O8" value="21.053" lower_limit="8.00" upper_limit="54.55"/>
                    <measurement group_id="O9" value="-17.891" lower_limit="-27.39" upper_limit="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab 6 mg Q3M</title>
          <description>Participants received denosumab 6 mg SC every 3 months (Q3M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E3">
          <title>Denosumab 14 mg Q3M</title>
          <description>Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E4">
          <title>Denosumab 30 mg Q3M</title>
          <description>Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.</description>
        </group>
        <group group_id="E5">
          <title>Denosumab 14 mg Q6M</title>
          <description>Participants received denosumab 14 mg SC every 6 months (Q6M) until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E6">
          <title>Denosumab 60 mg Q6M</title>
          <description>Participants received denosumab 60 mg SC every 6 months until Month 42.</description>
        </group>
        <group group_id="E7">
          <title>Denosumab 100 mg Q6M</title>
          <description>Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E8">
          <title>Denosumab 210 mg Q6M</title>
          <description>Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.</description>
        </group>
        <group group_id="E9">
          <title>Alendronate 70 mg</title>
          <description>Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus non-insulin-dependent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Follicle centre lymphoma, follicular grade I, II, III stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="41" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="42" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator’s discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

